ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026
ADMA Biologics (Nasdaq: ADMA) will report its second quarter 2026 financial results on August 5, 2026, after U.S. markets close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ADMA Biologics (Nasdaq: ADMA) will report its second quarter 2026 financial results on August 5, 2026, after U.S. markets close. Management will host a live conference call and audio webcast at 4:30 p.m. ET to discuss the results and provide company updates.
Participants must register in advance to receive dial-in details and a unique PIN. A replay will be available under “Events & Webcasts” in the investor section of ADMA’s website.
Details
News Market Reaction – ADMA
On Jul 29, the day this news came out, ADMA closed 0.91% below the previous close. Argus tracked a peak move of +14.9% during that session. Our momentum scanner recorded 2 alerts for this stock that day.
Data tracked by StockTitan Argus for the Jul 29 session.
Key Figures
- Reporting Date
- August 5, 2026
- Second-quarter 2026 financial results
- Conference Call Time
- 4:30 p.m. ET
- Management conference call and audio webcast
- Recommended Early Arrival
- 10 minutes
- Before the event start
- Publication Date
- July 29, 2026
- Company announcement dateline
Previous Earnings date Reports
-
Announcement scheduled first-quarter results and a 4:30 p.m. conference call.
-
Announcement scheduled fourth-quarter and full-year results after market close.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call Scheduled for August 5, 2026, at 4:30 p.m. ET
RAMSEY, N.J. and BOCA RATON, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report second quarter 2026 financial results on August 5, 2026, after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates.
To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and unique PIN. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time during the call). Attendees who will not be asking a question during the call are encouraged to listen in to the live webcast here. An archived replay of the event will be available located under “Events & Webcasts” in the investor section of the Company’s website at https://ir.admabiologics.com/events-webcasts.
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra
INVESTOR RELATIONS CONTACT:
Argot Partners | 212-600-1902 | ADMA@argotpartners.com
MEDIA CONTACT:
Longacre Square Partners | ADMABiologics@longacresquare.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.